Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine [FOLLOW-UP OF 700217216]

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Memantine (Primary)
Indications Asperger syndrome; Autistic disorder; Pervasive child development disorders
Focus Therapeutic Use
Sponsors Forest Laboratories

12 Jul 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
13 Jul 2013 Planned number of patients changed from 96 to 450 as reported by European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com